Our Team
Target ALS Team
We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.
Foundation Advisors
Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.
Leonard Petrucelli, Ph.D.
Chief Scientific Advisor, Target ALS
Professor of Neuroscience, Mayo Clinic
Board Members
The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly groundbreaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members, and visionary philanthropists.
Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & Former CEO, Sidewalk Labs Former CEO, Bloomberg LP Former Deputy Mayor of Economic Development and Rebuilding for the City of New York
Andy Berndt
Vice President and Co-Founder,
Google Creative Lab
Alisa Doctoroff
Philanthropist
John Dunlop, Ph.D.
Former Chief Scientific Officer,
Aliada Therapeutics
Steven Gruber
Investor
Zach Hall, Ph.D.
Former Director,
NIH NINDS
Richard Hargreaves, Ph.D.
Corporate Vice President,
Bristol-Myers Squibb
Chris Henderson, Ph.D.
Former Chief Scientific Officer,
Alltrna
Carole Ho, M.D.
Chief Medical Officer & Head of Development,
Denali Therapeutics
Allison Jaffin
Chief Operating Officer,
Bloomberg Philanthropies
Brad S. Karp
Chairman,
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Story Landis, Ph.D.
Former Director, NIH NINDS, Board Liaison, Independent Review Committee
Sarah I. Sheikh, BM BCh, MSc, MRCP
Senior Vice President, Neuroscience
Takeda
Stacie Weninger, Ph.D.
President and Venture Partner,
F-Prime Biomedical Research Initiative
Independent Review Committee
The Target ALS Independent Review Committee (IRC) evaluates and makes all research funding decisions. The IRC is comprised of experts across scientific disciplines from both industry and academia, reflecting the evolving nature of ALS research. To avoid any possible conflicts of interest, no member of the IRC can apply for or receive Target ALS funding for their own research. The committee is chaired by Robert Miller, Ph.D., George Washington University.
Michael Ahlijanian, Ph.D
Chief Scientific Officer,
Pinteon Therapeutics
Eva-maria Albers, Ph.D.
Professor and Group Leader, Institute for Developmental Biology and Neurobiology (IDN)
Johannes Gutenberg Universität Mainz
Sophia Bardehle, Ph.D.
Senior Principal Scientist, In Vivo Pharmacology,
Abbvie
Manzoor Bhat, Ph.D., M.S.
Vice Dean for Research (Interim), Professor and Chair,
UT Health Science Center, San Antonio
Dean Brown, Ph.D.
SVP and Head of Discovery Sciences,
Jnana Therapeutics
Elizabeth D. Buttermore, Ph.D.
Director of Translational In Vitro Models,
Rosamund Stone Zander Translational Neuroscience Center, Boston Children’s Hospital
Moses Chao, Ph.D.
Professor, Department of Neuroscience
and Physiology,
and Physiology,
New York University
Merit Cudkowicz, M.D.
Chief, Neurology Department; Director, Sean M. Healey & AMG Center for ALS; Julieanne Dorn Professor of Neurology,
Harvard Medical School
Vardhan Dani, Ph.D.
Michela Deleidi, M.D., Ph.D.
Helmholtz Group Leader, DZNE German Center for Neurodegenerative Diseases,
University of Tübingen
Nino Devidze, Ph.D.
VP, Medical,
SSI Strategy
Biljana Djukic, Ph.D.
Translational Medicine and Early Development Lead, Neurology and Rare Diseases,
Sanofi
Fanny Elahi, M.D., Ph.D.
Associate Professor
Icahn School of Medicine at Mount Sinai
Lisa Ellerby, Ph.D.
Professor,
Buck Institute
Kenneth Fischbeck, M.D.
NIH Distinguished Investigator,
NIH NINDS
Ana Fiszbein, Ph.D.
Assistant Professor of Biology,
Boston University
Brad Friedman, Ph.D.
Senior Principal Scientist, Department of OMNI Bioinformatics,
Genentech, Inc.
Judith Frydman, Ph.D.
Donald Kennedy Chair, School of Humanities and Sciences and Professor of Genetics,
Frydman Lab, Stanford University
Sonia Gandhi, M.D., Ph.D.
Professor of Neurology,
UCL and The Francis Crick Institute
Volkan Granit, MD, MSc
Medical Director, Clinical Development,
Biohaven Pharmaceuticals
Orla Hardiman, M.D., FRCPI
Professor of Neurology/Head of Academic, Clinical Medicine,
Trinity College of Dublin
Erika Holzbaur, Ph.D.
Professor of Physiology,
University of Pennsylvania, Perelman School of Medicine
Eric Huang, M.D., Ph.D.
Edward Mallinckrodt Professor & Chair,
Department of Pathology and Immunology, Washington University School of Medicine
Aimee Kao, M.D., Ph.D.
John Douglas French Foundation Endowed Professor; Director, Medical Scientist Training Program,
Memory and Aging Center, University of California, San Francisco
Zaven Kaprielian, Ph.D.
Chief Scientific Officer,
Remix Therapeutics
Holly Kordasiewicz, Ph.D.
Vice President, Neurology Research,
Ionis Pharmaceuticals
Sarah Kucenas, Ph.D
Professor of Biology, Cell Biology, and Neuroscience,
University of Virginia
Jim Kupiec, M.D.
Chief Clinical Development Officer,
Cassava Sciences
Claire Le Pichon, Ph.D.
Principal Investigator,
NIH Unit on the Development of Neurodegeneration
Pamela Maher, Ph.D.
Research Professor, Cellular Neurobiology Laboratory,
Salk Institute
Robert Mays, Ph.D.
Alexander McCampbell, Ph.D.
Global Head of Neuroscience & Rare Diseases Research,
Roche
Jere Meredith, Jr., Ph.D.
Senior Director, Head of Neurology Discovery,
Eisai Co, Ltd
Axel Methner, M.D.
Professor of Neurology,
University Medical Center Mainz
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Kelly Monk, Ph.D
Co-Director,
Vollum Institute
Ralda Nehme, Ph.D.
Principal Investigator & Director of Stem Cell Program,
Stanley Center for Psychiatric Research, Broad Institute of MIT & Harvard
Richard Olson, Ph.D.
Director, Small Molecule Drug Discovery,
Bristol Myers Squibb
Manuela Polydoro, Ph.D.
VP, Head of Translational Medicine,
Muna Therapeutics
Mahendra Rao, M.D., Ph.D.
Chief Executive Officer,
Implant Therapeutics
Ian Reynolds, Ph.D.
President,
YaghPenn Consulting
Tracy Saxton, Ph.D.
Managing Director,
Saxton Biopharma Consulting, LLC
Rob Scannevin, Ph.D.
Chief Scientific Officer,
Verge Genomics
Eric Schaeffer, Ph.D.
President,
Schaeffer Biopharma Consulting
Kimberly Scearce-Levie, Ph.D.
Chief Development Officer,
Cajal Neuroscience
Abdoulaye Sene, Ph.D.
VP, Translational Science, Ophthalmology,
Kartos Therapeutics
Holly Soares, Ph.D.
Global Head Neuroscience and Rare Disease Biomarkers, VP
Roche
Ajay Verma, M.D., Ph.D.
Ottavio Vitolo, M.D.
Lecturer on Psychology, Harvard University, Co-Founder, President and CEO, Vitam Therapeutics, Inc.,
Neuropsychiatrist, Massachusetts General Hospital
Frank Walsh, Ph.D.
Founder and Chief Executive Officer,
Ossianix
Andrew Wood, Ph.D.
VP, Clinical Neuroimaging Research,
CHDI
Nicholas Wood, Ph.Dd, FRCP, FMedSci
UCL Professor of Genetics and Neurology,
University College London, Institute of Neurology
Choya Yoon, Ph.D.
Associate Principal Scientist,
Merck
Stephen Zicha, Ph.D.
Neuroscience Search & Evaluation,
Eli Lilly & Co.
Conflict of Interest Committee
To avoid Conflicts of Interest (COI), all board and committee members, as well as staff, abide by a comprehensive COI policy and are neither allowed to apply for, nor receive funding from, Target ALS.
Chris Henderson, Ph.D.
Former Chief Scientific Officer,
Alltrna
Brad S. Karp
Chairman,
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Footer
Follow Us
Join us this ALS Awareness Month to discover the people, stories, and science accelerating progress in ALS research.